Report
EUR 13.26 For Business Accounts Only

An unfavourable environment weighs on CHINA NAT.MDC.CORP.LTD., which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of CHINA NAT.MDC.CORP.LTD. (CN), active in the Drug Retailers industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date June 23, 2017, the closing price was CNY 35.90 and its target price was estimated at CNY 31.24.
Underlying
China National Medicines Co. Ltd.

China National Medicines is engaged in the distribution of Chinese patent drugs, chemical drug, antibiotic, biomedicine, biological products, narcotic, first and second class of psychoactive drug and vaccine (valid till Jan 30 2010); sale of health care products (valid till Apr 12 2010); production of medicine; import and export business; provision of advisory services with regard to the above businesses; sale of II and III class of medical machine (valid till Nov 16 2011) and packaged food. Through its subsidiaries, Co. is also engaged in the provision of warehousing, logistic and information services.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch